News | ACC | July 15, 2022

ACC Names Dr. Melvin Echols as Chief Diversity, Equity and Inclusion Officer

The ACC has named Melvin R. Echols, MD, FACC, as its new Chief Diversity, Equity and Inclusion Officer

Melvin R. Echols, MD, FACC 


July 15, 2022 — The ACC has named Melvin R. Echols, MD, FACC, as its new Chief Diversity, Equity and Inclusion Officer, effective July 18. Echols will lead the College’s diversity, equity and inclusion strategy and programs, while also maintaining a portion of his current clinical and research responsibilities at Morehouse School of Medicine in Atlanta. 

"Fostering a diverse and inclusive cardiovascular workforce, while also advancing solutions to improve health equity among individual patients and populations, is fundamental to achieving ACC’s Mission of transforming cardiovascular care and improving heart health for all,” said ACC CEO Cathleen C. Gates. “As both a cardiologist and a cardiovascular disparities researcher, Dr. Echols brings a deep understanding of the profession, as well as demonstrated success in effectively advancing diversity, equity and inclusion initiatives and driving cultural change – competencies that will undoubtedly ensure we are able to deliver on our strategic diversity, equity and inclusion goals now and into the future.” 

Echols is currently an associate professor of cardiovascular disease at Morehouse School of Medicine and serves as program director for the Cardiovascular Disease Fellowship. He is also a practicing cardiologist specializing in heart failure and brings more than a decade of experience as a clinical trial investigator focusing on heart failure, quality improvement, social determinants of health, and health care disparities. In his role as Chief Diversity, Equity and Inclusion Officer, Echols will use his expertise and experiences to work with ACC members, staff, external partners and other stakeholders to identify and implement programmatic goals and develop actionable and sustainable solutions to achieving a more diverse, equitable and inclusive College and cardiovascular profession. Specifically, he will lead and facilitate ACC efforts to mitigate barriers to entry into the field of cardiology; build and expand educational initiatives like the new Internal Medicine Program; and lead and coordinate the diversity and inclusion efforts and training of both staff and members across the College. 

“In a time where polarization continues to permeate our society, we need the implicit core values of diversity, equity, and inclusion now more than ever,” Echols said. “I expect this role will permit me to listen actively, learn vigorously, and allow the needs of our society to lead the ACC towards impactful change.” 

Echols graduated from Morehouse School of Medicine in 2002 and completed Internal Medicine at Duke University in 2005. He completed his cardiovascular fellowship training at Duke University Medical Center. He is a member of the ACC, Association of Black Cardiologists, the Heart Failure Society of America, the American Society of Preventive Cardiology, and the American Heart Association

“The discovery of commonalities between people and culture while providing quality cardiovascular care to all is strengthened by diversity, and will ultimately improve health equity in our society,” Echols said. “Everyone has a part to play in this mission and should feel included in helping to make our society and the world better than yesterday.” 

For more information: www.acc.org 

Find more ACC22 conference coverage 


Related Content

News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
Subscribe Now